Introduction
============

Gouty arthritis (GA) is one of the most common types of inflammatory arthritis and is caused by the deposition of monosodium urate (MSU) crystals in and around joints. Elevated serum urate levels are recognized as an important risk factor for the development of GA ([@b1-etm-0-0-7816]). However, only \~10% of individuals with hyperuricaemia actually develop GA. Therefore, it has been suggested that hyperuricemia alone is not sufficient to cause GA ([@b2-etm-0-0-7816]). Although previous studies have identified several candidate risk genes (SLC2A9, ABCG2 and URAT1) associated with raised serum urate concentrations that increase the risk for an individual to develop GA ([@b3-etm-0-0-7816]--[@b5-etm-0-0-7816]), the exact pathogenesis of gout remains elusive. There may be other genes that are not associated with urate metabolism that also contribute to susceptibility to this disease.

Long non-coding RNAs (lncRNAs) are a group of RNA transcripts that are \>200 nt in length. Initially, they were thought to be 'transcriptional noise' due to their lack of significant open reading frames and protein-coding ability. The human genome encoded tens of thousands of lncRNAs ([@b6-etm-0-0-7816]). In the past decade, an increasing number of lncRNAs have been characterized. Certain lncRNAs have been indicated to have important roles in diverse biological processes, including cell development, tumorigenesis and immune response. lncRNAs exert critical functions in the transcriptional, post-transcriptional and epigenetic regulation of gene expression ([@b7-etm-0-0-7816]). Although several studies have identified lncRNAs involved in a series of human biological and disease-associated processes ([@b8-etm-0-0-7816],[@b9-etm-0-0-7816]), only isolated examples on the regulation of rheumatic diseases through lncRNAs have been provided and the roles of lncRNAs in the progression of GA have remained to be fully elucidated.

In the present study, lncRNA microarrays were performed to evaluate the global expression profile of lncRNAs in peripheral blood mononuclear cells (PBMCs) of GA patients. In a subsequent Bioinformatics analysis, the lncRNA functions were annotated by Gene Ontology (GO) analysis, pathway analysis and network analysis. Reverse transcription-quantitative (RT-q)PCR was used to validate several random lncRNAs that were upregulated and downregulated in the GA patients compared with those in the healthy controls (HCs). These results provide information for future studies on GA.

Patients and methods
====================

### Study population and ethical statement

All participants were recruited from the Department of Rheumatology of the Affiliated Hospital of North Sichuan Medical College (Nanchong, China) between February 2015 and July 2016. The study group consisted of 60 GA patients and 60 HC subjects. The diagnoses of GA were confirmed by a clinical endocrinology physician, according to the American College of Rheumatology classification criteria ([@b10-etm-0-0-7816]). The patients had not received any systemic anti-inflammatory treatments or drugs to control the production and elimination of uric acid prior to obtainment of the blood samples. According to the design of a matched case-control study, healthy subjects with no history of gout and without any systemic inflammatory disease were enrolled in the present study. All the participants were of Chinese Han descent. Blood samples from all participants were obtained in the morning following overnight fasting for at least 12 h, and were collected in sterile, single-use, anticoagulant-coated tubes and immediately sent to the laboratory for genetic testing.

### RNA isolation

Ficoll-Hypaque density gradient centrifugation was performed to isolate the PBMCs from total blood samples. Total RNA was extracted from PBMCs using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. RNA quantity and quality were measured using a NanoDrop ND-2000c spectrophotometer (Thermo Fisher Scientific, Inc.) All of the RNA samples were stored at −80°C until further use.

### Microarray analysis

Samples from three GA patients and three HC subjects were used for the lncRNA microarray analysis on an Agilent SurePrint G3 Gene Expression Microarrays for Human (v3) platform (part no. G4851C; Agilent Technologies). The RNA integrity of these samples was assessed with an Agilent Bioanalyzer 2100 (Agilent Technologies). In this study, RNA integrity number (RIN) and 28S to 18S rRNA ratio (28S/18S) were used as a criterion for RNA quality. Only samples with 2,100 RIN ≥7.0 and 28S/18S ≥0.7 were used. Total RNA was amplified and labelled with a Low Input Quick Amp Labeling Kit, One-Color (Agilent Technologies), following the manufacturer\'s protocol. Labelled cRNA (pmol Cy3/µg cRNA) was purified with an RNeasy mini kit (Qiagen GmBH). Each slide was hybridized with 1.65 µg Cy3-labelled cRNA using a Gene Expression Hybridization Kit (Agilent Technologies) in a hybridization oven (Agilent Technologies) according to the manufacturer\'s protocol. After 17 h of hybridization, slides were washed in staining dishes (Thermo Fisher Scientific, Inc.) with a Gene Expression Wash Buffer Kit (Agilent Technologies) following the manufacturer\'s protocol. Slides were scanned with an Agilent microarray scanner (Agilent Technologies) with default settings (dye channel: Green, scan resolution=3 µm, 20 bit). Data were extracted with Feature Extraction software 10.7 (Agilent Technologies). Raw data were normalized with a Quantile algorithm, with Gene Spring Software 11.0 (Agilent Technologies). Differentially expressed lncRNAs and mRNAs between the two groups were identified when fold-change ≥2.

### 'Cis' and 'Trans' analysis of lncRNAs

The cis role of lncRNA refers to the lncRNA acting on neighbouring target genes ([@b11-etm-0-0-7816],[@b12-etm-0-0-7816]). The protein-coding genes 10 kbp upstream or downstream of the lncRNAs were screened as potential 'cis'-interacting genes. The trans predictions were made using blast to identify complementary or similar sequences. The complementary energy between the two sequences was calculated by using RNAplex. The genes with e ≤-30 were selected as potential 'trans'-interacting genes ([@b13-etm-0-0-7816]).

### Gene Ontology (GO) enrichment and pathway analysis

GO analysis was used to identify functional terms in different categories enriched by the differentially expressed mRNAs ([www.geneontology.org](www.geneontology.org); release 2016-08-08) ([@b14-etm-0-0-7816]). The KEGG database ([www.genome.jp/kegg](www.genome.jp/kegg); release 79, 2016/07) was used to determine the biological pathways that were enriched by the differentially expressed mRNAs ([@b15-etm-0-0-7816]).

### RT-qPCR assay

The lncRNAs selected and the sequences of the primers that were used for qPCR are provided in [Table I](#tI-etm-0-0-7816){ref-type="table"}. GAPDH was used as the endogenous control. In brief, total RNA was extracted as described above and then reverse-transcribed into complementary (c)DNA using a PrimeScript^®^ RT Reagent kit with gDNA Eraser (Perfect Real Time; Takara Bio Inc.) following the manufacturer\'s protocol. The differential expression of lncRNAs that were identified in the microarray analysis was measured by qPCR using SYBR Green assays (Takara Bio Inc.). The reactions were performed in a final volume of 20 µl and included 10 µl Power SYBR Green PCR Master Mix, 0.4 µl ROX Dye, 0.5 µl final working concentration of 10 pmol/l of each of the forward and reverse primers, 2 µl cDNA and 6.6 µl nuclease-free water. The reactions were performed using a QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions for PCR were as follows: Pre-denaturation at 95°C for 10 min, and amplification for 40 cycles of denaturation at 95°C for 15 sec and elongation at 60°C for 1 min. All the experiments were performed in duplicate and the mean value was used for further analysis. Relative lncRNA concentrations were calculated using the *2*^−ΔΔCq^ *method* ([@b16-etm-0-0-7816]).

### Statistical analysis

Statistical analysis was performed using the SPSS 22.0 software package (IBM Corp.). To analyse differences in expression of individual lncRNAs or mRNAs in the microarray analysis, Student\'s t-tests were used. Regarding the results of the PCR analysis, the significance of differences in expression levels of lncRNAs were determined by the Kruskal-Wallis test or Mann-Whitney U-test. For statistical correlation, Spearman correlation coefficient was used. Fisher\'s exact test was used in the GO enrichment and KEGG pathway analyses. P\<0.05 was considered to indicate statistical significance.

Results
=======

### Overview of the lncRNA and mRNA profiles

The expression levels of the lncRNAs and mRNAs from three GA patients and paired control samples were analysed using lncRNA expression microarrays, which contained a total of 63,431 lncRNAs. All lncRNAs and mRNAs that were differentially expressed with a fold-change ≥2.0 between the GA and HC groups are provided in [Tables SI](#SD1-etm-0-0-7816){ref-type="supplementary-material"} and [SII](#SD1-etm-0-0-7816){ref-type="supplementary-material"}. Analysis of the microarray data revealed that 1,815 lncRNAs and 971 mRNAs were significantly differentially expressed in GA patients compared with those in the HC group. In total, there were 875 upregulated lncRNAs and 940 downregulated lncRNAs in GA patients compared with those in the HC group ([Fig. 1A](#f1-etm-0-0-7816){ref-type="fig"}). A total of 465 mRNAs were upregulated and 506 mRNAs were downregulated in the GA patients compared with those in the HC group ([Fig. 1B](#f1-etm-0-0-7816){ref-type="fig"}). [Table II](#tII-etm-0-0-7816){ref-type="table"} presents the 10 most upregulated and downregulated lncRNAs in the GA patients vs. HC group. Among these lncRNAs, AJ227913 (fold-change, 17.014) was the most upregulated lncRNA and 52094-1 (fold-change, 11.772) was the most downregulated lncRNA in the GA patients vs. HC group. [Table III](#tIII-etm-0-0-7816){ref-type="table"} lists the 10 most upregulated and downregulated mRNAs. The most significantly upregulated mRNA was NM_005217 (fold-change, 18.208), and the most downregulated mRNA was NM_005353 (fold-change, 14.047) in the GA patients vs. HC group. Studies have suggested that several lncRNAs regulate their own transcription in 'cis', as well as that of nearby genes, by recruiting remodelling factors to local chromatin ([@b11-etm-0-0-7816]). Therefore, the chromosomal co-expression was then analysed. According to this analysis, the lncRNAs had 148 'cis' genes and 145 'trans' genes. The downregulated lncRNAs had 233 'cis' genes and 338 'trans' genes (detailed results are displayed in [Tables SI](#SD1-etm-0-0-7816){ref-type="supplementary-material"} and [SII](#SD1-etm-0-0-7816){ref-type="supplementary-material"}).

### GO analysis

GO analysis was performed to identify the transcripts with terms that covered 3 domains ([Fig. 2](#f2-etm-0-0-7816){ref-type="fig"}): Biological process, cellular component and molecular function. Fisher\'s exact test was employed to determine if there was more overlap between the differentially expressed list and the GO annotation list than what would be expected by chance (P\<0.05 is recommended). The most highly enriched GO terms in the category molecular function were identified as 'binding', 'catalytic activity' and 'molecular transducer activity'. The most highly enriched GO terms in the category cellular component were 'cell' and 'cell part'. In the category biological process, the most highly enriched GO term was 'cellular process'. 'Metabolic process', and 'immune system process' were also significantly enriched.

### Pathway analysis

KEGG pathway analysis was performed for the differentially expressed transcripts. The pathway analysis indicated which biological pathways were significantly enriched for the differentially expressed transcripts. A total of 19 pathways corresponded to the differentially expressed transcripts ([Table IV](#tIV-etm-0-0-7816){ref-type="table"}). The gene category 'tumor necrosis factor (TNF) signaling pathway' was the most enriched network, promoting cell survival and differentiation, as well as immune and inflammatory responses ([@b17-etm-0-0-7816]). Furthermore, 8 transcripts were significantly enriched in the pathway 'osteoclast differentiation', which is closely linked to bone development and repair ([@b18-etm-0-0-7816]). Among these pathways, the 'NOD-like receptor signaling pathway' and 'NF-κB signaling pathway' ([Fig. 3](#f3-etm-0-0-7816){ref-type="fig"}) have been previously demonstrated to be involved in MSU-mediated inflammation through activation of Toll-like receptors/MyD88-dependent NF-κB signaling, NLR family pyrin domain containing 3 inflammasome and interleukin (IL)-1β/MyD88-dependent IL-1 receptor signalling ([@b19-etm-0-0-7816]).

### RT-qPCR validation

To validate the results of the microarray, four of the upregulated lncRNAs and two of the downregulated lncRNAs were selected for the RT-qPCR analysis of 60 GA patients and 60 HC subjects from a Han Chinese population. The results confirmed that the expression of AJ227913 (P\<0.05), AK001903 (P\<0.05), ENSG00000239182 (P\<0.05) and lnc-AP000769.1--1 (P\<0.05) was significantly increased in gouty arthritis patients compared with that in healthy subjects, whereas the expression of lnc-PCYOX1L-1:1 (P\<0.05) and lnc-CCDC64B-1:8 (P\<0.05) was significantly decreased in GA patients compared with that in healthy subjects. The fold changes of the normalized levels for the six lncRNAs were 17.02, 10.97, 7.71, 2.03, 2.31 and 2.05, respectively, in the gene chip analysis comparing the GA to the HC groups. Regarding the expression levels in the RT-qPCR analysis, these fold changes were 10.76, 7.64, 4.15, 3.16, 2.03 and 2.50, respectively, in the GA group compared to those in the control group. Thus, the results of the RT-qPCR and the microarray data were consistent ([Fig. 4](#f4-etm-0-0-7816){ref-type="fig"}). Among the lncRNAs analysed, AJ227913 had the largest difference in the expression between the two groups. Furthermore, Spearman correlation analysis suggested that the expression levels of AJ227913 in GA patients were correlated with urea (r=0.618, P\<0.05), creatinine (r=0.382, P\<0.05) and cystatin C (r=0.482, P\<0.05; [Table SIII](#SD1-etm-0-0-7816){ref-type="supplementary-material"}).

Discussion
==========

Protein-coding genes account for only \~2% of the human genome, while a large proportion of the genome is transcribed to generate non-coding RNAs that have been estimated to comprise up to 98--99% of the genome ([@b20-etm-0-0-7816]). It has become apparent that mutations and abnormal regulation of certain lncRNAs have important roles in the occurrence and development of various rheumatic diseases ([@b21-etm-0-0-7816]). Luo *et al* ([@b22-etm-0-0-7816]) indicated that 8,868 lncRNAs were highly differentially expressed in systemic lupus erythematosus (SLE) samples compared with those in a healthy group, and overall, aberrant expression profiles of lncRNAs may provide important insight into the pathogenesis of SLE ([@b23-etm-0-0-7816]). Downregulation of lnc-dendritic cell lncRNA (lnc-DC) in the plasma of patients with SLE may regulate type 17 T-helper cell differentiation by regulating the expression of signal transducer and activator of transcription 3; thus, the plasma levels of lnc-DC may be a potential biomarker for SLE ([@b24-etm-0-0-7816],[@b25-etm-0-0-7816]). In rheumatoid arthritis (RA) patients, MALAT1 increases the expression of caspase-3 and caspase-9 and promotes cell growth and apoptosis of RA fibroblast-like synoviocyte cells. Methotrexate treatment increases the expression of lincRNA-p21 and inhibits NF-κB activity compared with those in untreated RA patients ([@b26-etm-0-0-7816],[@b27-etm-0-0-7816]). Patients with osteoarthritis (OA) were indicated to have high levels of lncRNA-CIR. Treatment of chondrocytes *in vitro* with IL-1β and TNF-α significantly increased the expression of lncRNA-CIR compared with that in the controls. Furthermore, silencing of lncRNA-CIR by small interfering RNA reduced the expression of matrix metalloproteinase (MMP)13 and ADAM metallopeptidase with thrombospondin type 1 motif 5 compared with that in the controls. Thus, lncRNA-CIR may act as a potential target in OA therapy ([@b28-etm-0-0-7816],[@b29-etm-0-0-7816]). To examine the functional implications of lncRNAs in GA, the expression profiles of lncRNAs in GA patients and in HCs were determined using microarrays.

In the present study, the lncRNA expression profiles in 3 GA patients and 3 HCs comprising 63,431 lncRNAs were assessed by microarray analysis. A total of 875 lncRNAs were significantly upregulated and 940 lncRNAs were significantly downregulated, which was by \>2-fold. A total of 6 lncRNAs, which were not previously reported by studies on other diseases, were then randomly selected for validation in 60 other GA patients and in paired HCs by RT-qPCR. The results of the RT-qPCR analysis were consistent with those of the microarray analysis. The differential expression of lncRNAs in GA implied that lncRNAs may have a crucial role in the onset and development of GA. However, further validations and functional studies are warranted in the future. In the present study, a significant increase in the expression level of AJ227913 in GA patients compared with that in HCs was identified based on the microarray analysis. The AJ227913 expression levels in GA patients had a close correlation with urea (r=0.618, P\<0.05), creatinine (r=0.382, P\<0.05) and cystatin C (r=0.482, P\<0.05) levels based on the Spearman correlation analysis. Most circulating uric acid is freely filtered in the kidney. Urea, creatinine, cystatin C and uric acid are crude indicators of renal filtration and excretory function. However, uric acid is excreted in urine in healthy humans. Uric acid excretion may be impaired by kidney disease, leading to chronic hyperuricaemia. High uric acid levels in the body may lead to glomerular filtration disorders and a decrease in renal tubular secretion. It may increase the risk of gout or gouty nephropathy ([@b30-etm-0-0-7816],[@b31-etm-0-0-7816]). These results suggest that AJ227913 may be involved in the dynamic balance of the production and elimination of uric acid in GA patients.

GO and pathway analyses were performed to predict the biological functions of the differentially expressed lncRNAs and potential mechanisms in GA progression. According to this analysis, the mostly highly enriched GO terms by the differentially expressed transcripts were binding, catalytic activity, molecular transducer activity, cellular process, cell and cell part. The GO project is a framework for modelling biology that may be used to describe the functional classification of differentially expressed transcripts. The pathway analysis suggested that the differentially expressed transcripts were associated with 19 pathways. The gene category 'TNF signaling pathway' promotes cell survival and differentiation, as well as immune and inflammatory responses ([@b17-etm-0-0-7816]). The 'osteoclast differentiation' process is known to be important for bone development and repair ([@b18-etm-0-0-7816]). In addition, the 'NOD-like receptor signaling pathway' and 'NF-κB signaling pathway' have been reported to participate in MSU-mediated signaling cascades, which induce inflammasome-dependent gouty inflammation ([@b19-etm-0-0-7816]). These results have prompted us to investigate the molecular mechanisms of the pathogenesis of gout, which is important for further studies.

Gene expression is a highly complex, regulated process with numerous levels of regulation (epigenetic, transcriptional, post-transcriptional, translational and posttranslational). lncRNAs act as essential regulators of gene expression at the epigenetic level. The results of the 'cis' analysis performed in the present study suggested that AJ227913 may regulate IL-8 expression. IL-8 is a member of the chemokine family and is a key inflammatory mediator, which has an important role in regulating inflammation and immunity in various rheumatic diseases. Significantly higher concentrations of IL-8 were detected in the synovial fluid of RA patients than in those of HCs. IL-8 may stimulate neutrophils to produce cartilage-degrading enzymes, which may lead to joint tissue damage in RA. Inhibiting IL-8 production has been reported to reduce joint damage, which may be a novel target for the treatment of RA ([@b32-etm-0-0-7816]--[@b34-etm-0-0-7816]). Previous studies have indicated a marked increase in IL-8 in the exudate from patients with psoriatic arthritis (PsA) compared with that in the controls. An IL-8 monoclonal antibody was approved as a topical treatment for PsA in China. The therapeutic effect of anti-IL-8 is thought to be associated with a decrease in the accumulation of neutrophils and inflammatory cells, leading to the reduction of inflammation in patients with PsA ([@b35-etm-0-0-7816]--[@b37-etm-0-0-7816]). These results suggest a pathogenic role for IL-8 in rheumatic diseases. GA is a type of inflammatory arthritis that is caused by the deposition of MSU crystals. Several lines of evidence indicate that IL-8 is an essential mediator of neutrophil-mediated acute inflammation. The levels of IL-8 are increased during the acute and intercritical phases of GA. MSU may stimulate the secretion of IL-8 by human neutrophils. In rabbits with MSU crystal-induced arthritis, intra-articular injection of anti-IL-8 significantly attenuated crystal-induced joint swelling ([@b38-etm-0-0-7816]--[@b40-etm-0-0-7816]). Therefore, it was hypothesized that AJ227913 may regulate IL-8 expression in GA patients, and is thus involved in the pathogenesis of GA. Further research focusing on the roles of AJ227913 may provide a novel strategy for the treatment of GA.

In summary, the present study determined the expression profiles of patients with GA vs. HCs using microarray and identified a collection of differentially expressed lncRNAs. To the best of our knowledge, the present study was the first to examine the lncRNA profiles in GA. The present results may indicate that the differential expression of various lncRNAs has an important role in the development and progression of GA. Further studies will focus on the biological function of lncRNAs involved in GA.
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###### 

Primer sequences used for validation of lncRNAs by reverse transcription-quantitative PCR.

  lncRNA              Forward primer (5′-3′)   Reverse primer (5′-3′)     Length (bp)
  ------------------- ------------------------ -------------------------- -------------
  AJ227913            TTTTGCCAAGGAGTGCTAAAGA   AACCCTCTGCACCCAGTTTTC      194
  AK001903            CCAGCGGATATTTTGGTGTTTG   AGAAGCTATCAGGCGTTGCTG      86
  ENSG00000239182     TAGCACTGTTGCCTGAGCCA     GGAAGGAGCAGCCCACAGC        95
  lnc-AP000769.1--1   CAAGCAGAAGCAACAGGTCA     GAGCCAGGAAGATTGGAGAA       144
  lnc-PCYOX1L-1:1     GGAAAGGCAGTAATCAACTCCA   ACTCCACAATCCCCACAGC        171
  lnc-CCDC64B-1:8     ACCCCCACCCCAGGTCTTC      GCTGTGTCTCTGTCTTGGTCTCTT   268
  GAPDH               ATCATCCCTGCCTCTACTG      AGTCAGAGGAGACCACCTG        241

lncRNA, long non-coding RNA.

###### 

Top 10 significantly differentially expressed lncRNAs between gouty arthritis patients and healthy controls.

  A, Upregulated lncRNAs                                                 
  ------------------------------ --------------------- ----------------- -------------
  AJ227913                       NONCODERv3            17.014            0.035
  AK001903                       NONCODERv3            10.971            0.016
  THC2686626                     Agilent_HUMAN_G3V2    9.332             0.034
  TCONS_00026568                 Agilent_HUMAN_G3V2    8.450             0.008
  lnc-COL20A1                    lncipedia2.1          7.833             0.038
  ENST00000604411.1              gencode_v17           7.741             0.020
  lnc-AP000769.1--1              lncipedia2.1          7.710             0.006
  TCONS_00026396                 Agilent_HUMAN_G3V2    7.607             0.008
  TCONS_00018683                 Agilent_HUMAN_G3V2    7.526             0.026
  TCONS_l2_00003767              Agilent_HUMAN_G3V2    6.914             0.012
                                                                         
  **B, Downregulated lncRNAs**                                           
                                                                         
  **lncRNA name**                **Source database**   **Fold change**   **P-value**
                                                                         
  52094-1                        UCSC                  11.772            0.001
  TCONS_l2_00000650              Agilent_HUMAN_G3V2    11.392            0.007
  CR616125                       NONCODERv3            9.367             0.012
  lnc-KCNT2                      lncipedia2.1          8.885             0.018
  BX538226                       NONCODERv3            8.794             0.001
  ENST00000430519                Agilent_HUMAN_G3V2    8.410             0.025
  lnc-APTX-1                     lncipedia2.1          7.178             0.001
  TCONS_l2_00007044              UCSC                  7.000             0.033
  37475-1                        NONCODERv3            6.935             0.017
  AK056081                       Agilent_HUMAN_G3V2    6.894             0.048

lncRNA, long non-coding RNA; UCSC, University of California Santa Cruz.

###### 

Top 10 significantly differentially expressed mRNAs between gouty arthritis patients and healthy controls.

  A, Upregulated mRNAs                                               
  ------------------------------ ----------------- ----------------- -------------
  NM_005217                      DEFA3             18.208            0.050
  NM_014364                      GAPDHS            14.277            0.003
  NM_173557                      RNF152            11.779            0.032
  NM_000584                      IL8               11.616            0.030
  DB514319                       NA                11.600            0.028
  NM_002192                      INHBA             11.220            0.029
  THC2725968                     XLOC_002791       10.485            0.017
  ENST00000511330                XLOC_003547       9.264             0.001
  NM_003955                      SOCS3             9.186             0.002
  NM_001964                      EGR1              8.8103            0.043
                                                                     
  **B, Downregulated mRNAs**                                         
                                                                     
  **Primary accession number**   **Gene symbol**   **Fold change**   **P-value**
                                                                     
  NM_005353                      ITGAD             14.047            0.007
  ENST00000435913                NA                8.365             0.016
  NM_015267                      CUX2              8.346             0.042
  NR_026970                      LY86-AS1          8.068             0.033
  ENST00000400449                NA                7.909             0.014
  AK095683                       PSMG4             7.880             0.037
  NM_021161                      KCNK10            7.879             0.022
  LNCA_33_P3384628               NA                7.670             0.010
  NM_080747                      KRT72             7.656             0.008
  NR_040093                      LOC100505678      7.343             0.016

DEFA3, defensin, α 3; GAPDHS, glyceraldehyde-3-phosphate dehydrogenase, testis-specific; RNF152, ring finger protein 152; IL-8, interleukin 8; INHBA, inhibin β A; SOCS, suppressor of cytokine signalling; EGR1, early growth response protein 1; CUX2, cut like homeobox 2; ITGAD, integrin α-D; LY86-AS1, LY86 antisense RNA 1; PSMG4, proteasome assembly chaperone 4; KCNK10, potassium channel subfamily K member 10; KRT72, keratin, type II cytoskeletal 72; NA, not available.

###### 

KEGG pathway analysis of differentially expressed transcripts.

  Term       Description                                                  Count   P-value   Enrichment score
  ---------- ------------------------------------------------------------ ------- --------- ------------------
  hsa05134   Legionellosis                                                6       0.001     5.217
  hsa04621   NOD-like receptor signaling pathway                          6       0.001     5.034
  hsa04610   Complement and coagulation cascades                          7       0.001     4.238
  hsa05150   Staphylococcus aureus infection                              5       0.007     4.195
  hsa04668   TNF signaling pathway                                        11      0.000     3.913
  hsa05140   Leishmaniasis                                                6       0.004     3.878
  hsa04978   Mineral absorption                                           4       0.023     3.679
  hsa05120   Epithelial cell signaling in Helicobacter pylori infection   5       0.014     3.516
  hsa04012   ErbB signaling pathway                                       6       0.010     3.261
  hsa05133   Pertussis                                                    5       0.020     3.188
  hsa04064   NF-κB signaling pathway                                      10      0.013     3.085
  hsa05131   Shigellosis                                                  4       0.047     2.943
  hsa04380   Osteoclast differentiation                                   8       0.006     2.898
  hsa05132   Salmonella infection                                         5       0.034     2.780
  hsa05142   Chagas disease (American trypanosomiasis)                    6       0.021     2.759
  hsa05161   Hepatitis B                                                  7       0.033     2.293
  hsa04024   cAMP signaling pathway                                       9       0.023     2.163
  hsa05205   Proteoglycans in cancer                                      9       0.028     2.100
  hsa05166   HTLV--I infection                                            8       0.020     2.031

Hsa, *Homo sapiens*; ErbB, epidermal growth factor; NOD, nucleotide binding oligomerization domain; TNF, tumor necrosis fator; NF-κB, nuclear factor κB; cAMP, cyclic adenosine monophosphate; HTLV--I, human T-lymphotropic virus 1.

[^1]: Contributed equally
